Content area
Full Text
Alizyme is a biotechnology company based in Cambridge, UK, whose drug development programme focuses on therapies for the treatment of obesity, constipation-predominant irritable bowel syndrome (C-IBS) and mixed-syndrome irritable bowel syndrome (m-IBS), ulcerative colitis and mucositis resulting from chemotherapy or radiotherapy. The company does not yet have any turnover.
During the six month period Alizyme spent £7.3m on research and development compared with £4.6m for the comparative six month period in 2002, and .£509,000 on management and administration, down from £567,000 for the six months ended 30th June, 2002. Over the period under review, cash and short-term investments increased by £10.1m from £5.3m to £15.4m,...